The U.S. Food and Drug Administration (FDA) has approved Qamzova, a non-opioid, long-acting painkiller developed in China. The medication is being hailed as a potential breakthrough in the fight against the nation’s ongoing fentanyl overdose crisis.
Qamzova, produced by Nanjing-based biotech firm Delova, is the first China-invented analgesic to gain FDA approval. The drug is a non-steroidal anti-inflammatory (NSAID) that delivers continuous 24-hour pain relief through a single injection, significantly reducing the need for opioid-based treatments following surgery.
Clinical trials have shown that Qamzova can dramatically cut reliance on opioids such as morphine, with one study indicating its use nearly halved morphine consumption after orthopedic and abdominal surgeries. Backed by Sino Biopharmaceutical, which holds the commercial rights to the drug, Qamzova is now being positioned as a safer, non-addictive alternative for moderate-to-severe post-operative pain.
“This is a critical advancement,” said a Shanghai-based anesthetist involved in the trials. “Unlike current treatments that often require multiple injections and come with risks of addiction and side effects, Qamzova offers continuous relief with a single dose.”
The FDA’s approval not only introduces a new weapon against the U.S. opioid epidemic but also marks a milestone for China’s pharmaceutical innovation, which has faced scrutiny amid tensions over fentanyl precursor exports. The U.S. has accused China of not doing enough to curb the flow of chemicals used in the production of fentanyl, while Beijing has countered that it is being scapegoated for a broader American crisis.
Despite the geopolitical backdrop, medical experts see Qamzova’s arrival as a potentially transformative moment in the field of pain management. “This drug could help alleviate the dependency on opioids and reduce overdose deaths, though long-term studies are needed to monitor its safety and potential for misuse,” said Li Jianhua, a drug abuse researcher in China’s Yunnan province.
Qamzova also boasts a promising safety profile. Sino Biopharm reports it is well-tolerated, even among elderly patients and those with mild kidney issues — groups traditionally considered at higher risk for complications from surgery and conventional painkillers.
Pain management in the U.S. has long relied on opioid analgesics like oxycodone and hydrocodone, medications with high addiction risks and side effects including sedation and respiratory depression. According to the American Psychiatric Association, millions of Americans misuse prescription opioids annually, with overdose deaths fueled by synthetic opioids like fentanyl reaching alarming levels.
Founded in 2017, Delova has focused its research on non-opioid treatments, aiming to fill critical gaps in pain management. With Qamzova now approved both in the U.S. and China, its developers hope it will provide a global model for non-addictive pain control.
As Qamzova begins its rollout, healthcare professionals and policymakers alike are watching closely. For a country grappling with a devastating opioid epidemic, the arrival of this innovative, foreign-developed medication could not be timelier.
